High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma

Tissue Antigens

Volumn 85, Issue 6, 2015, Pages 476-483

  Samuels, S ^a   Ferns, D M ^b   Meijer, D ^c   van Straalen, J P ^c   Buist, M R ^c   Zijlmans, H J ^a   Kenter, G G ^a,b,c   Jordanova, E S ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; Cervical cancer; Soluble human leukocyte antigen G; Soluble major histocompatibility complex class I chain related molecule A; Survival

Indexed keywords

HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1; MHC CLASS I-RELATED CHAIN A; TUMOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UPREGULATION; UTERINE CERVIX CARCINOMA; ADENOSQUAMOUS CARCINOMA; BLOOD; CANCER STAGING; COMPARATIVE STUDY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SOLUBILITY; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SOLUBILITY; UTERINE CERVICAL NEOPLASMS;

EID: 84929050541     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12562     Document Type: Article

References (51)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [internet]. 2013. http://globocan.iarc.fr.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002: 55: 244-65.
3. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999: 189: 12-9.
4. Evander M, Edlund K, Gustafsson A et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995: 171: 1026-30.
5. Du C, Wang Y. The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res 2011: 30: 12.
6. Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res 2008: 68: 627-30.
7. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006: 118: 684-7.
8. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 2008: 8: 16.
9. Duan X, Deng L, Chen X et al. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011: 28: 466-74.
10. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006: 55: 1584-9.
11. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004: 114: 560-8.
12. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002: 169: 4098-102.
13. Jordanova ES, Gorter A, Ayachi O et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008: 14: 2028-35.
14. Chung HW, Lim JB. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma. Cancer Sci 2011: 102: 1673-9.
15. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002: 419: 734-8.
16. Diefenbach A, Tomasello E, Lucas M et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002: 3: 1142-9.
17. Bonnafous C et al. Targeting MICA with therapeutic antibodies for the treatment of cancer. J Immuno Therapy Cancer 2013: 1 (Suppl. 1): P41.
18. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005: 65: 10139-44.
19. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 2007: 17: 469-79.
20. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003: 13: 371-7.
21. Zheng N, Wang CX, Zhang X et al. Up-regulation of HLA-G expression in cervical premalignant and malignant lesions. Tissue Antigens 2011: 77: 218-24.
22. Park Y, Kim SJ, Lee SJ, Kim BS. Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma: does it have a prognostic value? Leuk Lymphoma 2008: 49: 1623-6.
23. Zhu CB, Wang CX, Zhang X, Zhang J, Li W. Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer 2011: 128: 617-22.
24. Provatopoulou X, Kalogera E, Sagkriotis A et al. Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy. Anticancer Res 2012: 32: 1021-6.
25. Schutt P, Schutt B, Switala M et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 2010: 71: 489-95.
26. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009: 105: 107-8.
27. Kochan G, Escors D, Breckpot K, Guerrero-Setas D. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2013: 2: e26491.
28. Cai MB, Han HQ, Bei JX et al. Expression of human leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma. Int J Biol Sci 2012: 8: 891-900.
29. Cai MY, Xu YF, Qiu SJ et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res 2009: 15: 4686-93.
30. Lin A, Zhang X, Zhou WJ et al. Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma. Int J Cancer 2011: 129: 1382-90.
31. Li XJ, Zhang X, Lin A, Ruan YY, Yan WH. Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. Hum Immunol 2012: 73: 946-9.
32. Rodriguez JA, Galeano L, Palacios DM et al. Altered HLA class I and HLA-G expression is associated with IL-10 expression in patients with cervical cancer. Pathobiology 2012: 79: 72-83.
33. Kumar V, Yi Lo PH, Sawai H et al. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PLoS One 2012: 7: e44743.
34. Tamaki S, Sanefuzi N, Kawakami M et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol 2008: 69: 88-93.
35. Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013: 78: 120-9.
36. Chitadze G, Lettau M, Bhat J et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer 2013: 133: 1557-66.
37. Chen Y, Lin G, Guo ZQ, Zhou ZF, He ZY, Ye YB. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS One 2013: 8: e69044.
38. Watson NF, Spendlove I, Madjd Z et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 2006: 118: 1445-52.
39. Lu J, Aggarwal R, Kanji S et al. Human ovarian tumor cells escape gammadelta T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS One 2011: 6: e23348.
40. Kusanagi Y, Kojima A, Mikami Y et al. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol 2010: 177: 2169-75.
41. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001: 37: 246-50.
42. Castellsague X, Diaz M, de Sanjose S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006: 98: 303-15.
43. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003: 88: 63-73.
44. Tornesello M, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med 2014: 12: 255.
45. Wright AA, Howitt BE, Myers AP et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013: 119: 3776-83.
46. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES. HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med 2012: 10: 184.
47. Wieten L, Mahaweni NM, Voorter CEM, Bos GMJ, Tilanus GJ. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens 2014: 84: 523-35.
48. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health 2012: 21: 1031-1037.
49. Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer 2000: 89: 1291-1299.
50. Williams NL, Werner TL, Jarboe EA, Gaffney DK. Adenocarcinoma of the cervix: should we treat it differently? Curr Oncol Rep 2015: 17: 440.
51. Fujiwara K, Mork B, Devouassoux-Shisheboran M. Adenocarcinoma of the uterine cervix: why is it different? Curr Oncol Rep 2014: 16: 416.